UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR) saying they see a modest impact from the narrowed AdCom vote, discussion. Despite ultimately voting for approval, panellists at today's FDA AdCom on SNY/REGN's Praluent appeared to suggest initial approval be restricted to a narrow patient population (HeFH), with further action likely dependent on CVOT data.

"While this result was more negative than we had expected, given the specific concerns raised by panel members, the implication and read-through to ESPR are much less clear," Peters commented. "Indeed, we believe many of the issues raised today may ultimately prove specific to the PCSK9s, and that being several years behind in development could end up benefiting ETC-1002. Further, in a worst-case scenario, a 2yr commercial delay pending CVOT data has a modest impact on our model, hence we reiterate our Buy rating and see weakness as overdone."

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $100.53 yesterday.